Yubo International Biotech Limited
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsYubo International Biotech Ltd is a U.S. holding company with a Cayman Islands and Hong Kong intermediary structure that operates through a variable interest entity in China, focused on endometrial stem cell research and consumer health products.
What they do
Yubo operates through Yubo International Biotech (Beijing) Limited, a VIE, which conducts day-to-day business in China. The company is focused on research and development and application of endometrial stem cells, aiming to build the first public endometrial stem cell repository. It offers products under the brand 'VIVCELL' including respiratory healthcare, skincare, hair care, healthy beverages, and personal care products, plus stem cell related services like cell testing and health management consulting.
Revenue drivers
- Healthcare products for respiratory system — Part of VIVCELL product line; specific revenue share not disclosed in filings.
- Skincare products — Consumer product line under VIVCELL brand; no separate revenue figures provided.
- Hair care products — Consumer product line under VIVCELL brand; no separate revenue figures provided.
- Stem cell related services — Includes cell testing and health management consulting; no separate revenue figures provided.
Recent performance
Annual revenue was $12,353 in 2025, down from $3,470 in 2024, after a peak of $604,676 in 2023. Net loss in 2025 was $1.1 million, improving from a $1.8 million loss in 2024. Quarterly revenue was $12,353 in Q4 2025 and $0 in the first two quarters of 2026, with Q1 2026 also reporting zero revenue. Operating cash flow was negative $842,802 in 2025. As of June 30, 2026, total assets were $672,272, total liabilities were $3.3 million, and shareholder equity was negative $2.6 million, with cash and equivalents of $11,989.
Strategy
The company's stated focus is on advancing endometrial stem cell research and building a public endometrial stem cell repository. It operates under the VIVCELL brand, selling healthcare and personal care products in China. The corporate structure relies on contractual arrangements with Yubo Beijing, and the company has not reported any new strategic initiatives or investments in the provided excerpts.
Risks
- VIE structure legal uncertainty — Contractual arrangements with Yubo Beijing have not been tested in court; PRC government could find them non-compliant, leading to penalties or loss of interests.
- Zero revenue quarters — Reported zero revenue in Q1 and Q2 2026, and Q3 2025, indicating minimal or no sales activity.
- Negative shareholders' equity — As of June 30, 2026, shareholders' equity was negative $2.6 million, with cash of only $11,989, raising going-concern risks.
- History of auditor changes — The company changed accountants three times between January 2025 and January 2026, which may indicate financial reporting instability.
Outlook
The company's outlook is not clearly articulated in the provided excerpts. Management has not provided specific forward-looking guidance. The company continues to highlight the risks of its VIE structure and China operations, which could materially affect its value. Given the zero revenue quarters and limited cash, the near-term outlook appears highly uncertain.